WS #16061
AbbVie presented long-term data showing sustained remission rates for Rinvoq and Skyrizi in inflammatory bowel disease, alongside promising Phase 2/3 data for ABBV-706 in small cell lung cancer. Eli Lilly also updated Phase 3 data for selpercatinib in medullary thyroid cancer. These clinical successes reinforce the defensive growth profile of large-cap healthcare stocks, providing a hedge against the broader macroeconomic uncertainty driven by energy shocks.
Healthcare Clinical Catalysts
AbbVie presented long-term data showing sustained remission rates for Rinvoq and Skyrizi in inflammatory bowel disease, alongside promising Phase 2/3 data for ABBV-706 in small cell lung cancer. Eli Lilly also updated Phase 3 data for selpercatinib in medullary thyroid cancer. These clinical successes reinforce the defensive growth profile of large-cap healthcare stocks, providing a hedge against the broader macroeconomic uncertainty driven by energy shocks.